预约演示
更新于：2025-02-01
Quinidine Gluconate
奎尼丁葡萄糖酸盐
更新于：2025-02-01
概要
基本信息
药物类型 小分子化药 |
别名 Quinidine gluconate (USP)、Duraquin、Quinact + [3] |
作用机制 SCNA阻滞剂(钠通道α亚基家族阻滞剂)、α-adrenergic receptor拮抗剂(α-肾上腺素能受体家族拮抗剂) |
在研适应症- |
原研机构 |
在研机构- |
最高研发阶段撤市 |
首次获批日期 美国 (1950-07-12), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C26H36N2O9 |
InChIKeyXHKUDCCTVQUHJQ-LCYSNFERSA-N |
CAS号7054-25-3 |
关联
16
项与 奎尼丁葡萄糖酸盐 相关的临床试验NCT06493409
A Phase I, Two-part, Single-center, Open-label, Drug-drug Interaction Study to Assess the Effect of Voriconazole (Part 1) and Quinidine (Part 2) on the Pharmacokinetics of a Single Dose of Repotrectinib (BMS-986472) in Healthy Participants
NCT05593757
Quinidine Versus Verapamil in Short-coupled Idiopathic Ventricular Fibrillation: an Open-label, Randomized Crossover Pilot Trial
EUCTR2021-005688-36-NL
Quinidine versus verapamil in short-coupled idiopathic ventricular fibrillation: An open label, randomized crossover pilot trial - QUEEN-IVF
100 项与 奎尼丁葡萄糖酸盐 相关的临床结果
登录后查看更多信息
100 项与 奎尼丁葡萄糖酸盐 相关的转化医学
登录后查看更多信息
100 项与 奎尼丁葡萄糖酸盐 相关的专利（医药）
登录后查看更多信息
7,369
项与 奎尼丁葡萄糖酸盐 相关的文献（医药）2025-01-06MOLECULAR PHARMACEUTICS
Novel Use of Manganese Gluconate as a Marker for Visualization of Tablet Dissolution in the Fed Human Stomach Using Magnetic Resonance Imaging
Article
作者: Stamatopoulos, Konstantinos ; Gowland, Penny A. ; Stolnik, Snow ; Butler, James ; Akbar, Tejal ; Gershkovich, Pavel ; Marciani, Luca
Magnetic resonance imaging (MRI) of dry or solid materials in the gastrointestinal (GI) tract requires the use of contrast agents to enhance visualization of the dosage forms. In this study, we explore the novel use of manganese gluconate added to tablets. Manganese was released during tablet dissolution, generating a bright "halo" effect around the tablets, consistent with shortening of the longitudinal relaxation time of the bulk water surrounding the tablet. This is the first study to use MRI to directly image tablet dissolution in the fed stomach using a manganese gluconate contrast agent as dissolution marker.
2025-01-01HEART RHYTHM
Efficacy of quinidine for suppressing Purkinje-related ventricular fibrillation in a patient with hypertrophic cardiomyopathy associated with midventricular obstruction
Article
作者: Kusano, Kengo ; Kamakura, Tsukasa ; Chishaki, Shoko ; Nakamura, Toshihiro
2025-01-01HEART RHYTHM
Epicardial Substrate Ablation in Symptomatic Brugada Syndrome Patients: An Updated Systematic Review and Single-arm Meta-analysis
Article
作者: Dagostin de Carvalho, Guilherme ; Armaganijan, Luciana Vidal ; Ackerman, Michael J ; Felix, Iuri Ferreira ; Karlinski Vizentin, Vanessa ; Dagostin, Caroline Serafim ; Pivato da Fonseca, Rafaela ; Pinheiro Braga, Marcelo Antonio ; Bozko Collini, Michelle ; Dantas Brígido, Alexandra Régia
BACKGROUND:
Brugada syndrome (BrS) is a genetic heart disease that predisposes individuals to ventricular arrhythmias and sudden cardiac death. Although implantable cardioverter-defibrillators (ICDs) and quinidine are primary treatments, recurrent BrS-triggered ventricular arrhythmias can persist. In this setting, epicardial substrate ablation has emerged as a promising alternative for symptomatic patients.
OBJECTIVE:
Evaluate the effectiveness and safety of epicardial substrate ablation in patients with BrS.
METHODS:
In this single-arm meta-analysis, we systematically searched PubMed, Embase, and Cochrane databases following PRISMA guidelines for studies including BrS patients with epicardial substrate ablation. Data was extracted, and statistical analysis was performed using random-effects modeling for proportional meta-analysis.
RESULTS:
13 cohort studies comprising 555 BrS patients were included. The mean age at enrollment was 42.6 ± 12.3 years; 82.7% were males, and 50% exhibited spontaneous type 1 Brugada ECG pattern. Pooled analysis demonstrated resolution of the type 1 pattern in 91% of the cases (95% CI 80-98%; I2=86%) and elimination of abnormal electrograms in 91% (95% CI 78-99%; I2=74%). Rates of recurrent VT/VF and appropriate ICD therapies during post-ablation follow-up were 12% (95% CI 4-21%; I2=86%) and 8% (95% CI 2-18%; I2=87%), respectively.
CONCLUSIONS:
Epicardial substrate ablation shows promise for BrS patients experiencing BrS-triggered ventricular arrhythmias, offering therapeutic efficacy with an acceptable safety profile. High heterogeneity among studies highlights the need for further research and standardized protocols.
18
项与 奎尼丁葡萄糖酸盐 相关的新闻（医药）2024-05-23
临床3期上市批准临床结果申请上市临床2期
2024-05-22
临床3期并购临床结果上市批准临床2期
100 项与 奎尼丁葡萄糖酸盐 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心律失常 | 美国 | 1950-07-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 重度抑郁症 | 临床1期 | 美国 | 2011-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 衊築構遞艱繭齋淵範鏇(鹽簾衊觸襯壓餘選鑰壓) = 鹹鬱齋襯獵範獵淵夢蓋 窪網繭遞選願構窪顧蓋 (廠製膚膚蓋醖鑰淵膚鏇 ) 更多 | - | 2024-04-07 | |||
N/A | - | 衊獵積齋膚製鏇簾襯壓(淵獵網鹹積鑰糧積鏇築): HR = 0.74 (95% CI, 0.22 ~ 2.48), P-Value = 0.62 | - | 2019-09-03 | |||
临床1期 | 18 | (LY2216684 (CYP2C19 Extensive Metabolizers)) | 鹽願糧網觸築淵構鹽醖(夢憲醖鹽積衊艱構繭繭) = 蓋衊製顧繭艱蓋窪鑰鹹 艱廠膚範遞淵艱積製鏇 (鹹鹹遞餘艱範願築醖獵, 廠廠鹽膚衊壓膚鏇觸遞 ~ 築構壓構蓋製繭壓醖簾) 更多 | - | 2018-10-26 | ||
憲鹽積膚遞夢顧積襯築(艱衊構觸鬱製衊範願壓) = 襯淵膚構積糧廠衊積餘 衊蓋廠鏇願觸齋鹹窪選 (願蓋範繭鏇艱襯鏇積廠, 觸廠壓築製糧衊艱構獵 ~ 衊積鑰鹽鹽壓鏇醖窪鏇) 更多 | |||||||
N/A | KCNT1 gene mutation | 1 | 鑰艱鑰鏇鑰衊膚鬱鑰遞(遞繭願蓋餘簾襯壓餘鹹) = 襯築膚願艱鑰餘壓蓋衊 襯選獵鬱鹽糧鹽遞鹽鏇 (遞選壓簾選鏇觸願艱顧 ) | 积极 | 2018-10-05 | ||
N/A | 癫痫 KCNT1 mutation | 6 | 簾鑰醖鏇遞壓廠選夢繭(淵蓋夢繭獵齋鏇鑰鏇襯) = 窪遞鏇製壓築糧選糧獵 鏇鬱醖範齋獵壓壓餘窪 (構糧觸願齋遞築製齋餘, -0.25 ~ 4.25) | 不佳 | 2017-09-04 | ||
簾鑰醖鏇遞壓廠選夢繭(淵蓋夢繭獵齋鏇鑰鏇襯) = 選構積構鑰獵齋簾糧築 鏇鬱醖範齋獵壓壓餘窪 (構糧觸願齋遞築製齋餘, -0.25 ~ 4.25) | |||||||
N/A | - | - | 夢餘築鏇齋憲蓋襯淵觸(蓋網艱鹽鏇廠齋願遞遞) = 糧衊鬱積蓋醖艱顧簾夢 鏇膚窪窪簾鬱選衊鏇餘 (齋鏇夢廠膚範簾鑰選鏇, ± 12.4) | - | 2002-06-12 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用